PetCaseFinder

Peer-reviewed veterinary case report

Eye pressure and pupil size changes in normal dogs after latanoprost

By Sarchahi, Ali Asghar et al.·Published in Veterinary ophthalmology·2012·Department of Clinical Studies·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs.

Species:
dog

Plain-English summary

Fifteen healthy mixed-breed dogs were given eye drops containing either latanoprost, pilocarpine, or a combination of both to see how they affected eye pressure and pupil size. Over five days, all treatments significantly lowered eye pressure compared to untreated eyes, with the combination showing a slight edge, though not enough to be considered better. All dogs experienced smaller pupils and some redness in the eyes during treatment. Overall, both medications were effective in reducing eye pressure, but the combination did not provide additional benefits.

People also search for: dog eye pressure treatment · latanoprost for dogs · pilocarpine side effects in dogs

Abstract

OBJECTIVE: To assess changes in intraocular pressure (IOP) and pupil diameter (PD) induced by daily application of an unfixed combination of latanoprost and pilocarpine in normal dogs. ANIMALS STUDIED: Fifteen mixed breed clinically normal dogs of both sexes. PROCEDURES: Three groups of five dogs each were administered in the right eye, one drop of 0.005% latanoprost (group L), 2% pilocarpine (group P), and 0.005% latanoprost with 2% pilocarpine (group LP), respectively. The left eyes received placebo. Drugs were administered once a day at 8 a.m. over a period of 5 days. IOP and PD measurements were conducted daily at 8 a.m., 10 a.m., 12 noon, 2 p.m., and 4 p.m. from 1 day preceding treatment to 7 days following treatment, and the presence of blepharospasm and/or conjunctival hyperemia was noted. RESULTS: Compared to baseline values, mean diurnal IOPs significantly decreased during the treatment period, by 4.4 (24.4%), 5.8 (31.4%), and 6.1 mmHg (35%) in the L, P, and LP groups, respectively. Compared to placebo-treated eyes, reductions of 2.1(14.1%), 3.2 (20.1%), and 4.1 mmHg (26.6%) were observed for the L, P, and LP groups, respectively. Although mean IOPs in the LP group decreased slightly more than the other two groups, these differences were not statistically significant. Miosis and conjunctival hyperemia were observed in the treated eyes of all three groups of animals during the treatment period. CONCLUSIONS: Although both 0.005% latanoprost and 2% pilocarpine individually produced significant decrease in IOP, the topical administration of a combination of latanoprost (0.005%) and pilocarpine (2%) was not associated with a statistically significant synergistic reduction in IOP in dogs; and miosis was the most frequent side effect observed during treatment.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22050700/